ZSCAN25 Antibody

What is ZSCAN25 and what are its key functional domains?

ZSCAN25 (Zinc finger and SCAN domain containing 25), also known as ZNF498, is a protein predicted to function as a DNA-binding transcription factor with RNA polymerase II-specific activity. The protein contains two key structural domains: a SCAN domain involved in protein-protein interactions and multiple zinc finger domains that facilitate DNA binding. The human ZSCAN25 protein has a molecular weight of approximately 61.5 kDa, although some sources report it as 30 kDa, which might represent a specific isoform or processed form of the protein . The presence of zinc finger domains suggests its role in transcriptional regulation through sequence-specific DNA binding, making it a target of interest in gene expression studies .

How do I choose between antibodies targeting different regions of ZSCAN25?

When selecting ZSCAN25 antibodies, consider your experimental objectives and the structural features of the target:

• N-terminal targeting antibodies: Best for studying the SCAN domain function. Available antibodies like ABIN501884 use synthetic peptides directed towards the N-terminal region (MLKEHPEMAE APQQQLGIPV VKLEKELPWG RGREDPSPET FRLRFRQFRY) . These are particularly useful when you need to distinguish between isoforms that differ in their C-terminal regions.

• C-terminal targeting antibodies: More suitable for detecting the zinc finger domains predominantly found in the C-terminal region. Antibodies like ABIN3187557 use synthesized peptides derived from the C-terminal region . These may be better for applications where the N-terminus might be obscured due to protein interactions.

• Function-specific considerations: For transcription factor activity research, consider antibodies targeting the zinc finger domains. For protein-protein interaction studies, N-terminal antibodies may be more informative .

For critical applications, use multiple antibodies targeting different regions to cross-validate findings, especially in novel research involving ZSCAN25.

Why do commercial sources report different molecular weights for ZSCAN25?

The discrepancy in reported molecular weights for ZSCAN25 (61.5 kDa vs. 30 kDa) can be explained by several methodological considerations:

• Protein isoforms: Alternative splicing may produce different isoforms with varying molecular weights .

• Post-translational modifications: Modifications such as phosphorylation, glycosylation, or proteolytic processing can significantly alter the apparent molecular weight on SDS-PAGE.

• Tissue-specific expression patterns: Different tissues may express different isoforms or post-translationally modified variants of ZSCAN25 .

• Experimental conditions: Differences in sample preparation, gel concentration, or running conditions can affect protein migration.

When encountering such discrepancies, run Western blots with positive controls and multiple antibodies targeting different epitopes to determine which form(s) are present in your experimental system. The DSHB antibody information indicates 61.5 kDa as the antigen molecular weight, while other sources report different sizes .

What are the optimal protocols for using ZSCAN25 antibodies in Western blotting?

Based on manufacturer recommendations and technical data from multiple antibody sources:

Sample Preparation:

• Extract proteins using standard lysis buffers containing protease inhibitors

• Prepare samples with 20-50 μg of total protein per lane in reducing sample buffer

Gel Electrophoresis and Transfer:

• Use 10-12% SDS-PAGE gels for optimal resolution of ZSCAN25 (reported MW range: 30-61.5 kDa)

• Include positive controls (cell lysates known to express ZSCAN25)

Antibody Incubation and Detection:

• Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Dilute primary ZSCAN25 antibody according to manufacturer's recommendations:

  • For polyclonal antibodies: 1:500-1:2000 dilution is recommended

  • For monoclonal antibodies: Follow specific recommendations in product data sheets

• Incubate with primary antibody overnight at 4°C with gentle agitation

• Wash 3-5 times with TBST, 5 minutes each

• Incubate with appropriate HRP-conjugated secondary antibody at 1:5000-1:10000 dilution

Critical Considerations:

• Expected bands: ~61.5 kDa (full-length) and possibly ~30 kDa (isoform or processed form)

• For low abundance of ZSCAN25, consider immunoprecipitation prior to Western blotting, as recommended for antibody PCRP-ZSCAN25-1A6

What controls should be included when using ZSCAN25 antibodies in immunofluorescence?

When conducting immunofluorescence experiments with ZSCAN25 antibodies, comprehensive controls are essential:

Positive Controls:

• Cell lines or tissues known to express ZSCAN25

• Overexpression systems where ZSCAN25 is exogenously expressed

Negative Controls:

• Primary antibody omission: Apply only secondary antibody to detect non-specific binding

• Isotype control: Replace ZSCAN25 antibody with non-immune IgG from the same host species

• Absorption control: Pre-incubate primary antibody with excess immunizing peptide to block specific binding

Specificity Controls:

• Multiple antibody validation: Use antibodies targeting different epitopes of ZSCAN25 (N-terminal vs C-terminal)

• Subcellular localization control: Co-staining with nuclear markers (as ZSCAN25 is a transcription factor)

Technical Controls:

• Autofluorescence control: Unstained sample to assess tissue/cell autofluorescence

• Blocking optimization: Test different blocking agents (BSA, normal serum, commercial blockers)

Including these controls provides a robust framework for ZSCAN25 immunofluorescence experiments, enhancing result reliability and facilitating troubleshooting of potential issues .

How do storage conditions affect ZSCAN25 antibody performance over time?

Proper storage of ZSCAN25 antibodies is critical for maintaining their performance:

Short-term Storage (Up to Two Weeks):

• Store at 4°C for immediate use

• Add 0.02-0.05% sodium azide as a preservative to prevent microbial growth (as mentioned in product specifications)

Long-term Storage (Beyond Two Weeks):

• Divide into small aliquots (20 μl minimum) to avoid repeated freeze-thaw cycles

• Store at -20°C or -80°C as recommended by all manufacturers

• Consider adding glycerol (equal volume) as a cryoprotectant for concentrated antibodies

Impact of Improper Storage on Performance:

• Repeated freeze-thaw cycles: Can lead to antibody denaturation, resulting in:

  • Reduced binding affinity

  • Increased background

  • Decreased signal intensity

• Prolonged storage at 4°C: May cause:

  • Microbial contamination (if preservative is inadequate)

  • Antibody degradation

  • Gradual loss of activity over time

Most manufacturers specify avoiding repeated freeze-thaw cycles , storing at -20°C , and using sodium azide as a preservative , indicating the importance of these storage practices for maintaining antibody performance.

How can ZSCAN25 antibodies be used to investigate gene-chemical interactions?

ZSCAN25 has been implicated in various chemical interactions according to toxicology databases. Here's a methodological approach to investigate these interactions:

Experimental Design for Chemical Exposure Studies:

• Dose-response assessment:

  • Treat cell or animal models with chemicals of interest at various concentrations

  • Based on documented interactions, chemicals like tetrachlorodibenzodioxin, acrylamide, bisphenol A, and amphetamine have shown effects on ZSCAN25 expression

Methodological Applications of ZSCAN25 Antibodies:

• Protein expression analysis:

  • Western blotting to quantify changes in ZSCAN25 protein levels after chemical exposure

  • Use antibodies targeting different epitopes to detect potential post-translational modifications

  • Recommended dilutions: 1:500-1:2000 for WB applications

• Chromatin association:

  • Chromatin immunoprecipitation (ChIP) using ZSCAN25 antibodies to identify DNA binding sites

  • ChIP-seq to map genome-wide changes in ZSCAN25 binding upon chemical exposure

Integration with Epigenetic Analysis:
Based on documented ZSCAN25 methylation effects with chemicals like bisphenol A :

• Combine ChIP with bisulfite sequencing to correlate ZSCAN25 binding with DNA methylation status

• Analyze histone modifications at ZSCAN25 binding sites before and after chemical exposure

Multiple studies have documented chemical-induced changes in ZSCAN25 expression and methylation, making antibody-based detection methods valuable for mechanistic toxicology research .

What methodological considerations exist when studying ZSCAN25's role as a transcription factor?

Investigating ZSCAN25's function as a transcription factor requires specialized approaches:

DNA Binding Characterization:

• Chromatin Immunoprecipitation (ChIP):

  • Select ZSCAN25 antibodies validated for immunoprecipitation applications

  • Based on technical data, antibodies like PCRP-ZSCAN25-1A6 are recommended for IP

  • Include appropriate controls (IgG, input DNA, positive control regions)

• DNA Binding Motif Identification:

  • ChIP followed by sequencing (ChIP-seq) to identify genome-wide binding sites

  • Electrophoretic Mobility Shift Assay (EMSA) with nuclear extracts and ZSCAN25 antibodies for supershift

Transcriptional Regulation Analysis:

• Reporter Assays:

  • Develop luciferase reporters containing putative ZSCAN25 binding sites

  • Perform site-directed mutagenesis of binding motifs to confirm functional importance

• Target Gene Validation:

  • Combine ChIP-seq with RNA-seq after ZSCAN25 modulation

  • Analyze correlation between binding events and gene expression changes

Protein-Protein Interaction Studies:

• Co-Immunoprecipitation:

  • Use ZSCAN25 antibodies to pull down protein complexes

  • Analyze by mass spectrometry to identify novel interaction partners

ZSCAN25's zinc finger domains suggest its role in specific DNA binding, while its SCAN domain indicates potential for protein-protein interactions, making both aspects important targets for investigation .

What optimization steps should I take if I observe weak or no signal with ZSCAN25 antibodies?

When faced with weak or absent signal using ZSCAN25 antibodies, a structured troubleshooting approach is essential:

Initial Assessment:

• Confirm target expression:

  • Verify ZSCAN25 expression in your experimental system at the mRNA level

  • Check public databases for expected expression levels in your tissue/cell type

  • Consider that ZSCAN25 expression may be regulated by chemicals/conditions (as shown in toxicology databases)

For Western Blotting:

• Sample preparation optimization:

  • Test different lysis buffers (RIPA, NP-40, SDS) to improve protein extraction

  • Include protease inhibitors to prevent degradation

• Protein loading and transfer:

  • Increase protein loading (50-100 μg per lane)

  • Optimize transfer conditions (time, voltage, buffer composition)

  • Use PVDF membranes for better protein retention

• Detection enhancement:

  • Increase primary antibody concentration (try 1:250 if 1:500 fails)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use more sensitive detection substrates

For Immunohistochemistry/Immunofluorescence:

• Antigen retrieval optimization:

  • Test multiple retrieval methods (heat-induced vs. enzymatic)

  • Vary pH conditions (citrate pH 6.0 vs. EDTA pH 9.0)

• Antibody detection enhancement:

  • Increase antibody concentration

  • Extend incubation time (overnight)

  • Use signal amplification systems (tyramide, polymer detection)

Manufacturers recommend specific dilution ranges (1:500-1:2000 for Western blot, 1:40000 for ELISA) , but optimization based on your specific samples and conditions is essential.

How can I minimize background when using ZSCAN25 antibodies in immunofluorescence?

High background is a common challenge in immunofluorescence with ZSCAN25 antibodies:

Pre-experimental Optimization:

• Antibody selection:

  • Choose antibodies specifically validated for immunofluorescence applications

  • Based on product specifications, select antibodies with demonstrated IF/ICC performance

• Fixation optimization:

  • Test different fixation methods:

    • 4% paraformaldehyde (preserves protein antigens)

    • Methanol (better for nuclear proteins like ZSCAN25)

• Blocking optimization:

  • Test different blocking solutions:

    • BSA (1-5%)

    • Normal serum (5-10%) from the same species as secondary antibody

  • Extend blocking time (1-2 hours) for challenging samples

Experimental Protocol Refinements:

• Antibody dilution and incubation:

  • Titrate primary antibody to find optimal concentration

  • Dilute antibodies in blocking buffer containing 0.1-0.3% Triton X-100

  • Incubate at 4°C overnight rather than at room temperature

• Washing optimization:

  • Increase number of washes (5-6 times)

  • Extend wash durations (10-15 minutes each)

  • Include detergent (0.05-0.1% Tween-20) in wash buffer

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Minimize concentration (typically 1:500-1:2000)

  • Protect from light to prevent fluorophore degradation

Background Reduction Strategies:

• Autofluorescence reduction:

  • Treat samples with sodium borohydride (10 mg/ml, 10 minutes)

  • Use Sudan Black B (0.1-0.3% in 70% ethanol) for lipofuscin quenching

• Non-specific binding reduction:

  • Pre-adsorb antibodies with acetone powder from relevant tissues

  • Add 100-150 mM NaCl to antibody diluent to increase stringency

These optimization strategies should be adapted based on the specific ZSCAN25 antibody being used and the particular tissue or cell type under investigation.